# Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

> **NCT04465097** · PHASE2 · COMPLETED · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucidinostat
- **DRUG:** Exemestane
- **DRUG:** Ovarian function suppression

## Key facts

- **NCT ID:** NCT04465097
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-08
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04465097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04465097, "Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04465097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*